CD112R Antikörper

Produktnummer ABIN6253480

Produktdetails

Target: CD112R

Reaktivität: Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Unkonjugiert

Applikation: ELISA, Western Blotting (WB)

Verwendungszweck: anti-CD112R (mouse), pAb (IN109)

Produktmerkmale: Polyclonal Antibody. Recognizes mouse CD112R. Does not cross-react with human CD112R. Source: Rabbit. Application: ELISA, WB. Liquid. In PBS containing 10 % glycerol and 0.02 % sodium azide. CD112 (also called Nectin-2 or poliovirus receptor-related 2 protein) is a type I transmembrane glycoprotein and a member of the Ig gene superfamily (IGSF). CD112/Nectin-2 functions as an adhesion molecule involved in the formation of cell junctions and interactions with other Nectin-family molecules. Nectin-2 is a also a surface marker of some endothelial cells and regulates migration, proliferation and angiogenesis. CD112 functions as an immune checkpoint regulator by modulating T cell signaling, either as a costimulator of T cell function, or as a coinhibitor of T cells proliferation by binding to the receptors CD226 or TIGIT (T cell Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain), respectively. The binding of CD112 ligand to these receptors is weak compared to CD155. Recently, a new receptor of CD112, called CD112R or PVRIG (Poliovirus receptor-related immunoglobulin domain-containing protein) has been characterized, showing high affinity to CD112. CD112R is a new coinhibitory receptor of the PVR family for human T cells, inhibiting TCR-mediated signals upon binding to CD112/Nectin-2. CD112R is preferentially expressed in T lymphocytes and NK cells. Cancer cells evade immune responses as a result of an immunosuppressive tumor microenvironment and CD112R, by playing a role in the regulation of the immune system, could be a new attractive cancer immunotherapy target.

Immunogen: Recombinant mouse CD112R.

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: Lot specific

Buffer: Liquid. In PBS containing 10 % glycerol and 0.02 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: After opening, prepare aliquots and store at -20 °C. Avoid freeze/thaw cycles.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung:

Short Term Storage: +4°C

Long Term Storage: -20°C

Use & Stability: Stable for at least 1 year after receipt when stored at -20°C.

Antigendetails

Target: CD112R

Hintergrund:

Alternate Names/Synonyms: CD112 Receptor, Poliovirus Receptor-related Immunoglobulin Domain-containing Protein, Transmembrane Protein PVRIG

Product Description: CD112 (also called Nectin-2 or poliovirus receptor-related 2 protein) is a type I transmembrane glycoprotein and a member of the Ig gene superfamily (IGSF). CD112/Nectin-2 functions as an adhesion molecule involved in the formation of cell junctions and interactions with other Nectin-family molecules. Nectin-2 is a also a surface marker of some endothelial cells and regulates migration, proliferation and angiogenesis. CD112 functions as an immune checkpoint regulator by modulating T cell signaling, either as a costimulator of T cell function, or as a coinhibitor of T cells proliferation by binding to the receptors CD226 or TIGIT (T cell Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain), respectively. The binding of CD112 ligand to these receptors is weak compared to CD155. Recently, a new receptor of CD112, called CD112R or PVRIG (Poliovirus receptor-related immunoglobulin domain-containing protein) has been characterized, showing high affinity to CD112. CD112R is a new coinhibitory receptor of the PVR family for human T cells, inhibiting TCR-mediated signals upon binding to CD112/Nectin-2. CD112R is preferentially expressed in T lymphocytes and NK cells. Cancer cells evade immune responses as a result of an immunosuppressive tumor microenvironment and CD112R, by playing a role in the regulation of the immune system, could be a new attractive cancer immunotherapy target.